CytomX Therapeutics, Inc. business relationships
Companies named in CytomX Therapeutics, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name CytomX Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 2 / 100 Top 5% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in CytomX Therapeutics, Inc.’s annual report 16
“This sublicense was incremental to the patents, patent applications and know-how covering conditionally activated T-cell engaging bispecific molecules that were developed and owned by the Company and licensed to Amgen.” SEC filing
“In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen.” SEC filing
“Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022.” SEC filing
“Under the Collaboration and License Agreement, the Company granted Regeneron an exclusive, worldwide, royalty-bearing license under certain Company intellectual property to develop, manufacture, commercialize and otherwise exploit licensed products ("Licensed Products") for all human and non-human d...” SEC filing
“We and Amgen collaborated in the research and development of conditionally activated T-cell engaging bispecifics therapies directed against such targets.” SEC filing
“We continued to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of PROBODY therapeutics against targets selected by Bristol Myers Squibb over the estimated research period, which ended in April 2025.” SEC filing
“In the second quarter of 2024, we announced a clinical collaboration with Merck to supply KEYTRUDA ® for evaluation of its combination with CX-801 in the Phase 1 study.” SEC filing
“Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics.” SEC filing
“Most recently, in November 2022 and December 2022, we entered into strategic collaborations with Regeneron and Moderna, respectively.” SEC filing
“Furthermore, the Amgen Other Products are accounted for as a separate performance obligation from the EGFR Products as the nature of the services being performed is not the same and the value that Amgen can derive from one program is not dependent on the success of the other.” SEC filing
“On March 12, 2026, CytomX Therapeutics, Inc. (the "Company") received written notice from Astellas Pharma Inc. ("Astellas") of Astellas's termination of the Collaboration and License Agreement, dated as of March 23, 2020, by and between Astellas and the Company (the "Agreement").” SEC filing
“The Company is also eligible to receive tiered royalties from high-single digit to low-teen percentage rates of annual global net sales of any products that are commercialized under the Moderna Agreement.” SEC filing
“Moderna will pay us tiered royalties on global net sales of Moderna Licensed Products from high single digit to low-teen percentages, subject to certain reductions.” SEC filing
“Additionally, we entered into a collaboration with Moderna for the development of mRNA based product candidates.” SEC filing
“Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics.” SEC filing
“In December 2019, the Company entered into a License Agreement (the "ImmunoGen 2019 License") with ImmunoGen, Inc. to obtain an exclusive license with respect to epithelial cell adhesion molecule ("EPCAM").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.